Literature DB >> 17592251

Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?

Chen Wei1, Wang Guomin, Liu Yujun, Qian Ruizhe.   

Abstract

The aim of this study is to investigate cancer stem cells and their markers in the prostate cancer cell line Du145. Different populations of cells were isolated from Du145. The clones formed by CD44+ integrinalpha(2)beta(1)+CD133+ cells are remarkably different morphologically and quantitatively from those formed by integrinalpha(2)beta(1)(-/low)CD133(-) cells. CD133(+) cells have the capacity for self renewal, extensive differentiation potential, and high proliferative and tumorigenic potential. CD34+ and CD117+ cells have no stem cell properties. Expression levels of c-myc and beta-catenin were elevated and bax was down regulated in CD44+ integrinalpha(2)beta(1)+CD133+ cells. In summary, CD44, integrinalpha(2)beta(1) and CD133 could be the cancer stem cell makers for the Du145 cell line. CD133+ cells differed significantly from CD44+ integrinalpha(2)beta(1)(-/low)CD133- cells and the total population in clone generation, genes expression, differentiation, proliferative and tumorigenic potential.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592251     DOI: 10.4161/cbt.6.5.3996

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  48 in total

Review 1.  Prostate cancer stem cell biology.

Authors:  C Yu; Z Yao; Y Jiang; E T Keller
Journal:  Minerva Urol Nefrol       Date:  2012-03       Impact factor: 3.720

2.  Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.

Authors:  Murielle Mimeault; Sonny L Johansson; Jean-Pierre Henichart; Patrick Depreux; Surinder K Batra
Journal:  Mol Cancer Ther       Date:  2010-02-23       Impact factor: 6.261

3.  Proliferation characteristics of CD133+ cell population in colorectal cancer.

Authors:  Dongdong Yu; Yonghong Zhang; You Zou; Jichao Qin; Xiaolan Li; Hui Xiao; Deding Tao; Junbo Hu; Jianping Gong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

4.  Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice.

Authors:  Mark E Stearns; Michael D Amatangelo; Devika Varma; Chris Sell; Shaun M Goodyear
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

Review 5.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

6.  Arachidonate 12-lipoxygenase may serve as a potential marker and therapeutic target for prostate cancer stem cells.

Authors:  Bo Yin; Yang Yang; Zhiqiang Zhao; Yu Zeng; Steven M Mooney; Ming Li; Xuewen Xu; Yongsheng Song; Bin Wu; Zhibo Yang
Journal:  Int J Oncol       Date:  2011-01-11       Impact factor: 5.650

Review 7.  Targeting prostate cancer stem cells for cancer therapy.

Authors:  Guocan Wang; Zhiwei Wang; Fazlul H Sarkar; Wenyi Wei
Journal:  Discov Med       Date:  2012-02       Impact factor: 2.970

8.  Expansion of prostate epithelial progenitor cells after inflammation of the mouse prostate.

Authors:  Liang Wang; Marloes Zoetemelk; Brahmananda R Chitteti; Timothy L Ratliff; Jason D Myers; Edward F Srour; Hal Broxmeyer; Travis J Jerde
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-29

9.  Cell-based selection provides novel molecular probes for cancer stem cells.

Authors:  Kwame Sefah; Kyung-Mi Bae; Joseph A Phillips; Dietmar W Siemann; Zhen Su; Steve McClellan; Johannes Vieweg; Weihong Tan
Journal:  Int J Cancer       Date:  2013-02-08       Impact factor: 7.396

Review 10.  Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.

Authors:  Murielle Mimeault; Parmender P Mehta; Ralph Hauke; Surinder K Batra
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.